Corrigendum to ‘‘Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)’’ [J Heart Lung Transplant 43 (2024) 272–283, (S1053249823020272), (10.1016/j.healun.2023.09.016)]

Vallerie McLaughlin, Harrison W. Farber, Kristin B. Highland, Anna R. Hemnes, Murali M. Chakinala, Kelly M. Chin, Michelle Han, Michelle Cho, Tobore Tobore, Mohammad Rahman, Nick H. Kim

Research output: Contribution to journalComment/debate

Abstract

The authors regret that the original version was published with errors in the Y-axes labels in Figure 1 and Figure 3. Figure 1 (A−D). The correct label for the Y-axis on each panel should be ‘‘Probability of patients free from hospitalization.” Figure 3 (A−E). The correct label for the Y-axis on each panel should be ‘‘Probability of remaining on therapy.’’ The corrected figures are included here. The authors would like to apologize for any inconvenience caused.

Original languageEnglish
JournalJournal of Heart and Lung Transplantation
DOIs
StateAccepted/In press - 2025

Fingerprint

Dive into the research topics of 'Corrigendum to ‘‘Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)’’ [J Heart Lung Transplant 43 (2024) 272–283, (S1053249823020272), (10.1016/j.healun.2023.09.016)]'. Together they form a unique fingerprint.

Cite this